BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ex-Synthes, Inc. (SYST) Execs Excluded From Programs


10/10/2012 7:32:00 AM

In the latest example in which the federal government is trying to get tougch with drug and device makers, former former executives at Synthes, which is now owned by Johnson & Johnson, have been excluded from participating in federal healthcare programs, according to details on the web site of the US Department of Health & Human Services Office of Inspector General. The move means that Michael Huggins, former head of Synthes North America; Tom Higgines, former head of Synthes Spine; former vp of operations Richard Bohner; and John Walsh, former head of regulatory affairs, will no longer be able to do business with such programs as Medicare and Medicaid. Effectively, this makes it significantly harder for them to obtain similar jobs, since nearly every company wants to do business with these programs. The exclusions are not surprising, though, given the sensational events that led the OIG to take this step. The former execs had recently served time in prison for their roles in unapproved clinical trials of a bone-cement drug that led to several patient deaths. All four pleaded guilty to one misdemeanor count of shipping an adulterated and misbranded product in interstate commerce.

Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->